Pathogenesis of Liver Fibrosis
The DOI matches its Crossref record; 220 of the 222 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
Liver fibrosis is a major cause of morbidity and mortality worldwide due to chronic viral hepatitis and, more recently, from fatty liver disease associated with obesity. Hepatic stellate cell activation represents a critical event in fibrosis because these cells become the primary source of extracellular matrix in liver upon injury. Use of cell-culture and animal models has expanded our understanding of the mechanisms underlying stellate cell activation and has shed new light on genetic regulation, the contribution of immune signaling, and the potential reversibility of the disease. As pathways of fibrogenesis are increasingly clarified, the key challenge will be translating new advances into the development of antifibrotic therapies for patients with chronic liver disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3, a member of the STATs family, is a key transcriptional mediator of cellular processes [43, 44].”
From Saikosaponin b1 Attenuates Liver Fibrosis by Blocking STAT3/Gli1 Interaction and Inducing Gli1 Degradation (2025) · cites this paper as [43]
In the citing paper
“they may also derive from portal fibroblasts, bone marrow-derived cells, circulating fibrocytes, [7] and by the controversially discussed epithelial-tomesenchymal (EMT) [8,9] or endothelial-to-mesenchymal (EndoTM) transition.[10,11]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [7]
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Origins and Mechanisms of miRNAs and siRNAs
Carthew, R. W., & Sontheimer, E. J. (2009) · Cell · doi:10.1016/j.cell.2009.01.035 · Cited by 5,018
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Self-citationMany roads to maturity: microRNA biogenesis pathways and their regulation
Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009) · Nature Cell Biology · doi:10.1038/ncb0309-228 · Cited by 2,656
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222
Bendelac, A., Savage, P. B., & Teyton, L. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141711 · Cited by 2,155
Research works printed but not linked: 15
- 10.1172/jci200112373 · DOI · Paper page
- 10.1055/s-2001-17556 · DOI · Paper page
- Stupack DG., 2007, Oncology, 21, 6
- Hehlgans S, 2007, Biochim. Biophys. Acta, 1775, 163
- Omenetti A, 2008, J. Clin. Investig., 118, 3331
- Pinzani M, 1996, Am. J. Pathol., 148, 785
- Sims DE., 1991, Can. J. Cardiol., 7, 431
- Thimgan MS, 1999, Am. J. Physiol., 277, G137
- 10.1136/gut.2005.088690 · DOI · Paper page
- Gao B., 2005, Cell Mol. Immunol., 2, 92
- Anania FA, 1995, Hepatology, 21, 1640
- Connolly MK, 2009, J. Clin. Investig., 119, 3213
- Seki E, 2009, J. Clin. Investig., 119, 1858
- McCrudden R, 2000, Histol. Histopathol., 15, 1159
- 10.1002/hep.23046 · DOI · Paper page
Cited by
Items 301–400 of 1,007
Defining Hepatic Dysfunction Parameters in Two Models of Fatty Liver Disease in Zebrafish Larvae
Howarth, D. L., Yin, C., Yeh, K., & Sadler, K. C. (2013) · Zebrafish · doi:10.1089/zeb.2012.0821 · Cited by 64
Martin, I. V., Borkham‐Kamphorst, E., Zok, S., van Roeyen, C. R. C., Eriksson, U., Boor, P., Hittatiya, K., Fischer, H., Wasmuth, H. E., Weiskirchen, R., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.09.006 · Cited by 64
Nevzorova, Y. A., Bangen, J., Hu, W., Haas, U., Weiskirchen, R., Gaßler, N., Huss, S., Tacke, F., Siciński, P., Trautwein, C., et al. (2012) · Hepatology · doi:10.1002/hep.25736 · Cited by 64
Sokar, S. S., El‐Sayad, M. E., Ghoneim, M. E.-S., & Shebl, A. M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.02.010 · Cited by 64
You, K., Li, S., Gong, J., Fang, J., Zhang, C., Zhang, M., Yuan, Y., Yang, J., & Zhuang, S. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.04.016 · Cited by 65
“It is characterized by excess accumulation of abnormal extracellular matrix (ECM) and disruption of hepatic architecture.(1,2) During liver fibrosis, ECM is converted from a collagen IV/VI-rich matrix to a collagen I/III-rich one, resulting in liver stiffness and distortion of the sinusoidal architecture.”
BackgroundHou, B., Zhao, Y., Qiang, G., Yang, X., Xu, C., Chen, X., Liu, C., Wang, X., Zhang, L., & Du, G. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/4545321 · Cited by 64
“Inflammatory cytokines play a key role in fibrosis [44]; thus, the persistent inflammation under diabetic condition almost always precedes fibrosis.”
BackgroundFighting against viral hepatitis: Lessons from Taiwan
Chen, D. (2011) · Hepatology · doi:10.1002/hep.24500 · Cited by 63
Embade, N., Mariñó, Z., Diercks, T., Cano, A., Lens, S., Cabrera, D., Navasa, M., Falcón‐Pérez, J. M., Caballería, J., Castro, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155094 · Cited by 63
Jia, H., Liu, J., Fang, T., Zhou, Z. D., Li, R., Yin, W., Qian, Y., Wang, Q., Zhou, W., Liu, C., et al. (2023) · Science Advances · doi:10.1126/sciadv.abq2937 · Cited by 64
“Recurrent liver injury leads to liver inflammation and fibrosis, even severe cirrhosis and hepatocellular carcinoma ( 4 , 5 ).”
Shao, W., Xu, H., Zeng, K., Ye, M., Pei, R., & Wang, K. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04139-2 · Cited by 65
Zhang, F., Kong, D., Zhang, Z., Lei, N., Zhu, X.-J., Zhang, X.-P., Chen, L., Lu, Y., & Zheng, S. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0791-5 · Cited by 63
da Silva, B. D. O., Ramos, L. F., & Moraes, K. C. M. (2017) · Cell Biology International · doi:10.1002/cbin.10790 · Cited by 64
Targeting CCl4‐induced liver fibrosis by RNA interference–mediated inhibition of cyclin E1 in mice
Bangen, J., Hammerich, L., Sonntag, R., Baues, M., Haas, U., Lambertz, D., Longerich, T., Lammers, T., Tacke, F., Trautwein, C., et al. (2017) · Hepatology · doi:10.1002/hep.29275 · Cited by 59
Advances in functional and molecular MRI technologies in chronic liver diseases
Zhou, I. Y., Catalano, O. A., & Caravan, P. D. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.020 · Cited by 63
“Liver fibrosis results from repeated hepatic injury which causes the chronic activation of tissue repair mechanisms to replace necrotic tissue with extracellular matrix (ECM) proteins [91].”
BackgroundLiu, C., & Chen, P. (2020) · Viruses · doi:10.3390/v12080815 · Cited by 63
“To develop effective anti-fibrotic or fibrinolytic therapies, we need to know more about the pathway and the genetic determinants of hepatic fibrosis [61].”
BackgroundMacrophage-specific FGF12 promotes liver fibrosis progression in mice
Li, S., Zhou, B., Xue, M., Zhu, J., Tong, G., Fan, J., Zhu, K., Hu, Z., Chen, R., Dong, Y., et al. (2023) · Hepatology · doi:10.1002/hep.32640 · Cited by 62
Ge, M., Liu, H., Zhang, N., Niu, W., Lu, Z.-N., Bao, Y., Huang, R., Yu, D., Shao, R., & He, H. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14873 · Cited by 62
Shah, R., Reyes‐Gordillo, K., Arellanes‐Robledo, J., Lechuga, C. G., Nazará, Z., Cotty, A., Rojkind, M., & Lakshman, M. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12167 · Cited by 62
Upregulation of SIRT1-AMPK by thymoquinone in hepatic stellate cells ameliorates liver injury
Yang, Y., Bai, T., Yao, Y., Zhang, D., Wu, Y., Lian, L., & Nan, J. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.09.014 · Cited by 62
Zhou, L., Dong, X., Wang, L., Shan, L., Li, T., Xu, W., Ding, Y., Lai, M., Lin, X., Dai, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17453 · Cited by 62
Fu, K., Ma, C., Wang, C., Zhou, H., Gong, L., Zhang, Y., & Li, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113185 · Cited by 61
Zhou, S., Li, W., Shi, F., Zhou, Z.-W., Li, B., Zhang, K., Zhang, X., Ouyang, C., & Zhu, X. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s85426 · Cited by 61
Current understanding of insulin resistance in hepatitis C
Kaddai, V., & Negro, F. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.43 · Cited by 61
Antifibrotics in chronic liver disease: tractable targets and translational challenges
Ramachandran, P., & Henderson, N. C. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30110-8 · Cited by 50
Suppression of SUN2 by DNA methylation is associated with HSCs activation and hepatic fibrosis
Chen, X., Li, W., Chen, Y., Li, X., Li, H.-D., Huang, H., Bu, F., Pan, X., Yang, Y., Huang, C., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1032-9 · Cited by 61
Hall, K. C., Bernier, S. G., Jacobson, S., Liu, G., Zhang, P. Y., Sarno, R., Catanzano, V., Currie, M. G., & Masferrer, J. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821045116 · Cited by 62
“These normally quiescent pericytes transdifferentiate into myofibroblasts that inappropriately secrete extracellular matrix (3).”
BackgroundHepatoprotective activity of silymarin encapsulation against hepatic damage in albino rats
Mukhtar, S., Zeng, X., Qamer, S., Saad, M., Mubarik, M. S., Mahmoud, A. H., & Mohammed, O. B. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.10.063 · Cited by 61
“It may develop into cirrhosis within 1–10 years (Hernandez-Gea and Friedman, 2011).”
BackgroundIn Vitro Liver Toxicity Testing of Chemicals: A Pragmatic Approach
Tabernilla, A., Rodrigues, B. D. S., Pieters, A., Caufriez, A., Leroy, K., Campenhout, R. V., Cooreman, A., Gomes, A. R., Arnesdotter, E., Gijbels, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095038 · Cited by 61
“The most progressive form of fibrosis is called cirrhosis, which is considered an irreversible event [282,283].”
BackgroundAldaba-Muruato, L. R., Moreno, M. G., Shibayama, M., Tsutsumi, V., & Muriel, P. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.09.018 · Cited by 61
Li, Z., Zhang, H., Li, Q., Feng, W., Jia, X., Zhou, R., Huang, Y., Li, Y., Hu, Z., Hu, X., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-02257-1 · Cited by 62
“(a) The cell trajectories inferred for myeloid cells (monocytes, macrophages and dendritic cells) colored by pseudotime with differentiation direction labeled with arrows; (b) The cell trajectories inferred for myeloid cells (monocytes, macrophages and dendritic cells) colored by cell types; (c) The comparison of pseu…”
BackgroundNotch signaling mediated by TGF-β/Smad pathway in concanavalin A-induced liver fibrosis in rats
Wang, Y., Shen, R.-W., Han, B., Li, Z., Xiong, L., Zhang, F.-Y., Cong, B.-B., & Zhang, B. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i13.2330 · Cited by 60
Li, S., Han, S., Jin, K., Yu, T., Chen, H., Zhou, X., Tan, Z., & Zhang, G. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.63889 · Cited by 60
Padinharayil, H., Varghese, J., Wilson, C. M., & George, A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122542 · Cited by 61
Demirören, K., Doğan, Y., Kocamaz, H., Özercan, İ. H., İlhan, S., Üstündağ, B., & Bahçecioğlu, İ. H. (2013) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2013.08.014 · Cited by 62
Zhang, F., Ni, C., Kong, D., Zhang, X., Zhu, X., Chen, L., Lu, Y., & Zheng, S. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.09.016 · Cited by 60
The Role of Mesothelial Cells in Liver Development, Injury, and Regeneration
Lua, I., & Asahina, K. (2016) · Gut and Liver · doi:10.5009/gnl15226 · Cited by 56
Ding, Q., Xie, X.-L., Wang, M.-M., Yin, J., Tian, J.-M., Jiang, X.-Y., Zhang, D., Han, J., Bai, Y., Cui, Z.-J., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0199-6 · Cited by 60
TGF-β1/p65/MAT2A pathway regulates liver fibrogenesis via intracellular SAM
Wang, K., Fang, S., Liu, Q., Gao, J., Wang, X., Zhu, H., Zhu, Z., Ji, F., Wu, J., Ma, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.058 · Cited by 57
“It is well recognized that aHSCs produce TGF-β1 or other cytokines to reinforce HSCs activation [1].”
BackgroundNi, H., Chao, X., Yang, H., Deng, F., Wang, S., Bai, Q., Qian, H., Cui, Y., Cui, W., Shi, Y., et al. (2019) · Hepatology · doi:10.1002/hep.30770 · Cited by 60
“2143 and eventual progression to liver tumorigenesis.(3-5) Interestingly, the mentioned conditions that lead to chronic liver injury are often associated with impaired hepatic autophagy, a lysosomal degradation pathway that plays an important role in regulating the homeostasis of cellular proteins, lipids, and organel…”
BackgroundDana, J., Venkatasamy, A., Saviano, A., Lupberger, J., Hoshida, Y., Vilgrain, V., Nahon, P., Reinhold, C., Gallix, B., & Baumert, T. F. (2022) · Hepatology International · doi:10.1007/s12072-022-10303-0 · Cited by 62
“It is mainly caused by sustained liver insults, resulting in pathological deposition of collagen extracellular matrix and, ultimately, parenchyma and vascular distortion with regenerative nodules [24].”
BackgroundActivation of Platelet-Derived Growth Factor Receptor Alpha Contributes to Liver Fibrosis
Hayes, B. J., Riehle, K. J., Shimizu-Albergine, M., Bauer, R. L., Hudkins, K. L., Johansson, F., Yeh, M. M., Mahoney, W. M., Yeung, R. S., & Campbell, J. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092925 · Cited by 59
The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity
Fu, K., Wang, C., Ma, C., Zhou, H., & Li, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.771459 · Cited by 61
Zhang, L., Deng, W., Huang, Q., Zhang, J., Wang, Y., Zhou, T., Xing, L., & Jiang, H. (2024) · Advanced Materials · doi:10.1002/adma.202311474 · Cited by 59
Wang, Z., Li, Y., Wang, X., Zhang, W., Chen, Y., Lu, X., Jin, C., Tu, L., Jiang, T., Yang, Y., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156796 · Cited by 59
Wu, L., Liu, S., Liu, Y., Guo, C., Li, H., Li, W., Jin, X., Zhang, K., Zhao, P., Wei, L. J., et al. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.03.003 · Cited by 59
Zhang, Z., Guo, Y., Zhang, S., Zhang, Y., Wang, Y., Ni, W., Kong, D., Chen, W., & Zheng, S. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.042 · Cited by 59
Bingül, İ., Başaran‐Küçükgergin, C., Aydin, A. F., Çoban, J., Doğan‐Ekici, I., Doğru‐Abbasoğlu, S., & Uysal, M. (2016) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2016.05.033 · Cited by 59
Yu, F., Guo, Y. G., Chen, B., Shi, L., Dong, P., Zhou, M., & Zheng, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000472410 · Cited by 59
Peng, Y., Yang, T., Huang, K., Shen, L., Tao, Y., & Liu, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00762 · Cited by 59
“The interactions between HSCs and hepatic immune cell subsets have emerged as important determinants of liver fibrosis progression and regression (Hernandez-Gea and Friedman, 2011).”
BackgroundRole of the intestinal microbiome in liver fibrosis development and new treatment strategies
Zhou, R., Fan, X., & Schnabl, B. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.005 · Cited by 60
Jiang, R., Zhou, Y., Wang, S., Pang, N., Huang, Y., Ye, M., Wan, T., Qiu, Y., Pei, L., Jiang, X., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.064 · Cited by 56
Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis
Bai, X., Su, G., & Zhai, S. (2020) · Nanomaterials · doi:10.3390/nano10101945 · Cited by 59
“ECM deposition changes the structure and function of liver tissue, which is the root cause of liver fibrosis [26,27].”
BackgroundCarvacrol alleviates liver fibrosis by inhibiting TRPM7 and modulating the MAPK signaling pathway
Cai, S., Wu, L., Yuan, S., Liu, G., Wang, Y., Fang, L., & Xu, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173982 · Cited by 60
Human adipose stem cell-derived extracellular nanovesicles for treatment of chronic liver fibrosis
Han, H. S., Lee, H., You, D., Nguyen, V. Q., Song, D.-G., Oh, B. H., Shin, S., Choi, J. S., Kim, J. D., Pan, C.-H., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.042 · Cited by 58
Liu, Y., Kong, X., You, Y., Xiang, L., Zhang, Y., Wu, R., Zhou, L., & Duan, L. (2022) · Cells · doi:10.3390/cells11223579 · Cited by 58
“However, in many cases, liver fibrosis progresses to cirrhosis over time and increases the risk of liver failure and hepatocellular carcinoma [1].”
BackgroundInfluentialZhang, K., Zhang, Y., Ai, W., Hu, Q., Zhang, Q., Wan, L., Wang, X.-L., Liu, C.-B., & Wu, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i3.878 · Cited by 58
Chronic liver inflammation: Clinical implications beyond alcoholic liver disease
Park, B., Lee, Y.-J., & Lee, H.-R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2168 · Cited by 60
Wen, S., Gao, J., Yang, W., Lu, Y., Tong, H., Huang, Z., Liu, Z., & Tang, C. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12641 · Cited by 58
F-actin cytoskeleton reorganization is associated with hepatic stellate cell activation
CUI, X., ZHANG, X., YIN, Q., MENG, A., SU, S., JING, X., LI, H., GUAN, X., LI, X., LIU, S., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2036 · Cited by 44
The Therapeutic Potential of Extracellular Vesicles Versus Mesenchymal Stem Cells in Liver Damage
Rostom, D. M., Attia, N., Khalifa, H. M., Nazel, M. W. A., & Sabaawy, E. A. E. (2020) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-020-00267-3 · Cited by 58
Yang, L.-X., Qi, C., Lu, S., Ye, X.-S., Merikhian, P., Zhang, D.-Y., Yao, T., Zhao, J.-S., Wu, Y., Jia, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55738-1 · Cited by 57
Shajari, S., Laliena, A., Heegsma, J., Tuñón, M. J., Moshage, H. J., & Faber, K. N. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12271 · Cited by 57
McKee, C., Sigala, B., Soeda, J., Mouralidarane, A., Morgan, M., Mazzoccoli, G., Rappa, F., Cappello, F., Cabibi, D., Pazienza, V., et al. (2015) · Scientific Reports · doi:10.1038/srep08812 · Cited by 54
Mechanisms of Accelerated Liver Fibrosis Progression during HIV Infection
Debes, J. D., Bohjanen, P. R., & Boonstra, A. (2016) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2016.00034 · Cited by 57
Zhou, S., Zhu, Y., Li, Z., Zhu, Y., He, Z., & Zhang, C. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16219 · Cited by 57
Salunkhe, S. A., Chitkara, D., Mahato, R. I., & Mittal, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.003 · Cited by 57
Thomas, R. G., Moon, M. J., Kim, J. H., Lee, J. H., & Jeong, Y. Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145512 · Cited by 56
Thirupathi, A., Silveira, P., Nesi, R. T., & Pinho, R. A. (2016) · Human & Experimental Toxicology · doi:10.1177/0960327116638727 · Cited by 56
“Therefore, attenuation of the fibrogenic process can significantly lower the morbidity.(5)”
BackgroundXiaochaihutang attenuates liver fibrosis by activation of Nrf2 pathway in rats
Li, J., Hu, R., Xu, S., Li, Y., Qin, Y., Wu, Q., & Xiao, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.065 · Cited by 56
Li, Z., Chen, B., Dong, W., Kong, M., Shao, Y., Fan, Z., Yu, L., Wu, D., Lu, J. L., Guo, J., et al. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00245 · Cited by 56
Königshofer, P., Hofer, B., Brusilovskaya, K., Simbrunner, B., Petrenko, O., Wöran, K., Herac, M., Stift, J., Lampichler, K., Timelthaler, G., et al. (2021) · Hepatology · doi:10.1002/hep.32220 · Cited by 56
Venkatesh, S. K., & Torbenson, M. S. (2022) · Abdominal Radiology · doi:10.1007/s00261-021-03396-y · Cited by 56
“When the injury to liver parenchyma is persistent due to a CLD, excessive and abnormal ECM deposition leads to progressive replacement of liver parenchyma by LF [2].”
BackgroundXie, W., Gan, J., Zhou, X., Tian, H., Pan, X., Liu, W., Li, X., Du, J., Xu, A., Zheng, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.020 · Cited by 55
Hepatitis B virus large surface protein: function and fame.
Churin, Y., Roderfeld, M., & Roeb, E. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2014.12.08 · Cited by 56
Ramachandran, S., Basha, H. I., Sarma, N. J., Lin, Y., Crippin, J. S., Chapman, W. C., & Mohanakumar, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070744 · Cited by 55
Efficacy and safety of anti-hepatic fibrosis drugs
Damiris, K., Tafesh, Z., & Pyrsopoulos, N. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i41.6304 · Cited by 56
Miao, H., Ouyang, H., Guo, Q., Wei, M., Lü, B., Kai, G., & Ji, L. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109020 · Cited by 55
Vrenken, K. S., Jalink, K., van Leeuwen, F. N., & Middelbeek, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.008 · Cited by 56
Gowifel, A. M. H., Khalil, M. G., Nada, S. A., Kenawy, S. A., Ahmed, K. A., Salama, M. M., & Safar, M. M. (2020) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2020.1801926 · Cited by 54
Interaction of hepatic stellate cells with diverse types of immune cells: Foe or friend?
Yi, H., & Jeong, W. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12017 · Cited by 54
Prediction of fibrosis progression in chronic viral hepatitis
Wong, G. L. (2014) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2014.20.3.228 · Cited by 54
Xu, T., Ni, M.-M., Xingli, Li, X., Meng, X., Huang, C., & Li, J. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.11.010 · Cited by 54
Astaxanthin prevents and reverses the activation of mouse primary hepatic stellate cells
Yang, Y. J., Bae, M., Kim, B., Park, Y., Koo, S. I., & Lee, J. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.11.005 · Cited by 54
Ren, L., Qi, K., Zhang, L., Bai, Z., Ren, C., Xu, X.-Y., Zhang, Z., & Li, X. (2019) · Biological Trace Element Research · doi:10.1007/s12011-019-1641-x · Cited by 54
Evaluation of spleen stiffness in healthy volunteers using point shear wave elastography
Giuffrè, M., Macor, D., Masutti, F., Abazia, C., Tinè, F., Patti, R., Buonocore, M. R., Colombo, A. A., Visintin, A., Campigotto, M., et al. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2019.03.004 · Cited by 54
Xu, L., & Liu, P. (2020) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2020.03.001 · Cited by 54
TIMP-1 signaling via CD63 triggers granulopoiesis and neutrophilia in mice
Kobuch, J., Cui, H., Grünwald, B. T., Säftig, P., Knolle, P. A., & Krüger, A. (2015) · Haematologica · doi:10.3324/haematol.2014.121590 · Cited by 54
Kim, D.-H., Kim, M.-J., Kwak, S.-Y., Jeong, J., Choi, D., Choi, S. W., Ryu, J., & Kang, K.-S. (2023) · Nature Communications · doi:10.1038/s41467-023-35941-2 · Cited by 53
Fang, X., Liu, L., Dong, J., Zhang, J., Song, H., Song, Y., Huang, Y., Cui, X., Lin, J., Chen, C., et al. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14081 · Cited by 53
Liver fibrosis is a common pathological change in the liver of dairy cows with fatty liver
Zhang, C., Shao, Q., Liu, M., Wang, Y., Loor, J. J., Jiang, Q., Cuan, S., Li, X., Wang, J., Li, Y., et al. (2023) · Journal of Dairy Science · doi:10.3168/jds.2022-22021 · Cited by 53
Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
Pessino, G., Scotti, C., Maggi, M., & Immuno-Hub Consortium (2024) · Cancers · doi:10.3390/cancers16050901 · Cited by 53
Zhang, D.-W., Zhao, Y.-X., Wei, D., Li, Y., Zhang, Y., Wu, J., Xu, J., Chen, C., Tang, H., Zhang, W., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.042 · Cited by 53
El‐Magd, N. F. A., El-Karef, A. A., El‐Shishtawy, M. M., & Eissa, L. A. (2015) · Egyptian Journal of Basic and Applied Sciences · doi:10.1016/j.ejbas.2014.12.005 · Cited by 53
The Effect of Antifibrotic Drugs in Rat Precision-Cut Fibrotic Liver Slices
Westra, I. M., Oosterhuis, D., Groothuis, G. M. M., & Olinga, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095462 · Cited by 53
Hepatitis C virus infection: establishment of chronicity and liver disease progression.
Kwon, Y., Ray, R. B., & Ray, R. (2014) · EXCLI journal · Cited by 53
Gajendiran, P., Vega, L. I., Itoh, K., Sesaki, H., Vakili, M. R., Lavasanifar, A., Hong, K. K., Mezey, E., & Ganapathy‐Kanniappan, S. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13501 · Cited by 53
Inorganic Nanomaterials as Highly Efficient Inhibitors of Cellular Hepatic Fibrosis
Peng, F., Tee, J. K., Setyawati, M. I., Ding, X., Yeo, H. L., Tan, Y. L., Leong, D. T., & Ho, H. K. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b10527 · Cited by 53
Lee, C.-Y., Suk, F., Twu, Y., & Liao, Y. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17113802 · Cited by 53
“indicated a transformation into myofibroblasts [30].”
BackgroundZong, Z., Liu, J., Wang, N., Yang, C., Wang, Q., Zhang, W., Chen, Y., Liu, X., & Deng, H. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.11.014 · Cited by 53
Ye, Q., Zhou, Y., Zhao, C., Xu, L., & Jian, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.677810 · Cited by 54
Metadata
- Authors
- Hernandez-Gea, V., & Friedman, S. L.
- Affiliations
- Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029;
- Icahn School of Medicine at Mount Sinai (US)
- ORCID
- Friedman, Scott L.
- Venue
- Annual Review of Pathology: Mechanisms of Disease
- Publisher
- Annual Reviews
- Published
- 2011-02-28
- Volume
- 6
- Issue
- 1
- Pages
- 425-456
- ISSN
- 1553-4006 (ISSN-L)
- 1553-4014
- OpenAlex
- W2142988890
- Cited by
- 1,809
- References
- 220
- Citations by year
- 2026: 81 · 2025: 123 · 2024: 121 · 2023: 112 · 2022: 148 · 2021: 174 · 2020: 145 · 2019: 119 · 2018: 117 · 2017: 131 · 2016: 136 · 2015: 124 · 2014: 97 · 2013: 76 · 2012: 67
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annual Review of Pathology Mechanisms of Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, hepatic stellate cell activation, extracellular matrix, chronic viral hepatitis, hepatic steatosis, obesity, immune signaling, genetic control, fibrosis reversibility, antifibrotic therapy, chronic liver disease
- MeSH terms
- Humans, Liver, Liver Cirrhosis, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.